The Neuspera Nuvella System is the first SNM device designed to provide a minimally invasive option. Credit: Neuspera Medical / PRNewswire.

Neuspera Medical has announced plans to begin the second phase of its SANS-UUI pivotal clinical trial of the Nuvella system.

The company plans to start enrolling 145 subjects at 25 sites across the world.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The single-arm clinical study has been designed to assess the Nuvella system’s safety and efficacy for the treatment of overactive bladder (OAB) in patients who have urinary urgency incontinence (UUI) symptoms.

It is said to be the first sacral neuromodulation (SNM) device designed to provide a minimally invasive option, which could allow better procedural versatility and patient experience.

Neuspera Medical founder and chief technology officer Alexander Yeh said: “We are very pleased the SANS-UUI trial has reached this important enrollment milestone, as we are now one step closer to bringing the life-changing benefits of this technology to patients.

See Also:

“The Nuvella system is the smallest available SNM device designed to minimise post-procedure discomfort and have no visible external appearance of the implant.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the feasibility phase of the SANS-UUI study, 34 subjects were implanted with the Nuvella system.

According to the findings, 90% of subjects showed an improvement of 50% in UUI symptoms at six and 12 months with two hours of daily stimulation.

At the 12-month visit, 52% of the subjects were completely dry, said the company.

Neuspera Medical chief medical officer Steven Siegel said: “In addition to the clinical benefits seen, Nuvella demonstrated safety consistent with other commercially available devices.”

The company is committed to developing implantable medical devices to improve the lives of patients with chronic diseases.

Including the Nuvella system, the Neuspera platform will provide patients and physicians with new and potentially earlier treatment options that are less invasive and more adaptable.